Skip to main content
SpringerLink
Log in

Hepatitis C Virus Infection in the Elderly

Epidemiology, Prophylaxis and Optimal Treatment

  • Disease Management
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Chronic infection with the hepatitis C virus (HCV) occurs throughout the world and appears to be the main cause of hepatocellular carcinoma.

Studies have shown that, in areas of high endemicity, the prevalence of HCV infection is low in children but high in people aged >60 years. Medical interventions were found to play an important role in the spread of HCV infection, because elderly patients became infected via contaminated blood transfusions or when contaminated syringes and needles were used. Maternal and sexual transmission do not appear to be the main routes of HCV infection.

Interferon treatment eliminates HCV in 20 to 30% of patients with chronic HCV infection. The response to interferon therapy is usually complete in 70 to 80% of people with low levels of HCV RNA, HCV of genotype 2 and young women, but poor in elderly patients. Because liver disease can be severe in elderly patients, more effective therapies are clearly needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tateda A, Kikuchi H, Numazaki Y, et al. Non-B hepatitis in Japanese recipients of blood transfusions: clinical and sero-logic studies after the introduction of laboratory screening of donor blood for hepatitis B surface antigen. J Infect Dis 1979; 139: 511–8

    PubMed  CAS  Google Scholar 

  2. Kiyosawa K, Akahane Y, Nagata A, et al. The significance of blood transfusion in non-A, non-B chronic liver disease in Japan. Vox Sang 1982; 43: 45–57

    PubMed  CAS  Google Scholar 

  3. Kiyosawa K, Akahane Y, Nagata A, et al. Hepatocellular carcinoma after non-A, non-B post-transfusion hepatitis. Am J Gastroenterol 1984; 79: 777–81

    PubMed  CAS  Google Scholar 

  4. Okuda H, Obata H, Motoike Y, et al. Clinicopathological features of hepatocellular carcinoma M comparison of hepatitis B seropositive and seronegative patients. Hepatogastro-enterology 1984; 31: 64–8

    CAS  Google Scholar 

  5. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359–62

    PubMed  CAS  Google Scholar 

  6. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362–4

    PubMed  CAS  Google Scholar 

  7. Yoshizawa H, Nojiri N, Takahashi K. Measurement of anti-GOR antibodies in prevention of post-transfusion non-A, non-B hepatitis. Lancet 1991; 337: 47–8

    PubMed  CAS  Google Scholar 

  8. Van der Poel CL, Cuypers HTM, Reesink HW, et al. Confirmation of hepatitis C virus infection by new four-antigen recom-binant blot assay. Lancet 1991; 337: 551–2

    Google Scholar 

  9. McHutchinson JG, Person JL, Govindarajan S, et al. Improved detection of hepatitis C virus antibodies in high-risk populations. Hepatology 1992; 15: 19–25

    Google Scholar 

  10. Hayashi J, Nakashima K, Kishihara Y, et al. Improved detection of antibodies to hepatitis C virus by the second-generation assay in patients with chronic non-A, non-B liver disease. J Infect 1993; 26: 287–94

    PubMed  CAS  Google Scholar 

  11. Hayashi J, Yoshimura E, Nabeshima A, et al. Seroepidemiology of hepatitis C virus infection in hemodialysis patients and the general population in Fukuoka and Okinawa, Japan. J Gastroenterol 1994; 29: 276–81

    PubMed  CAS  Google Scholar 

  12. Weiner AJ, Kuo G, Bradley DW, et al. Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet 1990; 355: 1–3

    Google Scholar 

  13. Okamoto H, Okada S, Sugiyama Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′ -noncoding region. Jpn J Exp Med 1990; 60: 215–22

    PubMed  CAS  Google Scholar 

  14. Inchauspe G, Abe K, Zebedee S, et al. Use of conserved sequences from hepatitis C virus for the detection of viral RNA in infected sera by polymerase chain reaction. Hepatology 1991; 14: 595–600

    PubMed  CAS  Google Scholar 

  15. Ulrich PP, Romero JM, Lane PK, et al. Detection, semiquantita-tion, and genetic variation in hepatitis C virus sequence amplified from the plasma of blood donors with elevated alanine aminotransferase. J Clin Invest 1990; 86: 1609–14

    PubMed  CAS  Google Scholar 

  16. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673–9

    PubMed  CAS  Google Scholar 

  17. Simmonds P, Alberti A, Bonino F, et al. A proposed system for the nomenclature for genotypes of hepatitis C virus. Hepatology 1994; 19: 1321–4

    PubMed  CAS  Google Scholar 

  18. McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32: 884–92

    PubMed  CAS  Google Scholar 

  19. Hayashi J, Kishihara Y, Yoshimura E, et al. Relationship of genotype to level of hepatitis C viraemia determined by competitive polymerase chain reaction. J Infect 1995; 30: 235–9

    PubMed  CAS  Google Scholar 

  20. Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci U S A 1989; 86: 9717–21

    PubMed  CAS  Google Scholar 

  21. Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RN A in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877–83

    PubMed  CAS  Google Scholar 

  22. Sherman KE, O’Brien J, Gutierrez AG, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993; 31: 2679–82

    PubMed  CAS  Google Scholar 

  23. Lau JYN, Davis GL, Kniffen J, et al. Significance of hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501–4

    PubMed  CAS  Google Scholar 

  24. Kuhnl P, Seidl S, Stängel W, et al. Antibody to hepatitis C virus in German blood donors [letter]. Lancet 1989; II: 324

    Google Scholar 

  25. Janot C, Courouce AM, Maneiz M. Antibodies to hepatitis C virus in French blood donors. Lancet 1989; II: 796–7

    Google Scholar 

  26. Sirchia G, Bellobuono A, Giovanetti A, et al. Antibodies to hepatitis C virus in Italian blood donors [letter]. Lancet 1989; II: 797

    Google Scholar 

  27. Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123: 330–7

    PubMed  CAS  Google Scholar 

  28. Serfaty L, Nousbaum JB, Elghouzzi MH, et al. Prevalence, severity, and risk factors of liver disease in blood donors positive in a second-generation anti-hepatitis C virus screening test. Hepatology 1995; 21: 725–9

    PubMed  CAS  Google Scholar 

  29. Watanabe J, Minegishi K, Mitsumori T, et al. Prevalence of anti-HCV antibody in blood donors in the Tokyo area. Vox Sang 1990; 59: 86–8

    PubMed  CAS  Google Scholar 

  30. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1996; 15: 5–14

    Google Scholar 

  31. Darwish MA, Raouf TA, Rushdy P, et al. Risk factors associated with a high seroprevalence of hepatitis C virus infection in Egyptian blood donors. Am J Trop Med Hyg 1993; 49: 440–7

    PubMed  CAS  Google Scholar 

  32. al-Faleh FZ, Ayoola EA, al-Jeffry M, et al. Prevalence of antibody to hepatitis C virus among Saudi Arabian children: a community-based study. Hepatology 1991; 14: 215–8

    PubMed  CAS  Google Scholar 

  33. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994; 330: 744–50

    PubMed  CAS  Google Scholar 

  34. Lin HH, Kao JH, Hsu HY, et al. Possible role of high-titer maternal viremia in perinatal transmission of hepatitis C virus. J Infect Dis 1994; 169: 638–41

    PubMed  CAS  Google Scholar 

  35. Osmond DH, Charlebois E, Sheppard HW, et al. Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men. J Infect Dis 1993; 167: 66–71

    PubMed  CAS  Google Scholar 

  36. Everhart JE, Di Bisceglie AM, Murray LM, et al. Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med 1990; 112: 544–5

    PubMed  CAS  Google Scholar 

  37. Osmond DH, Padian NS, Sheppard HW, et al. Risk factors for hepatitis C virus seropositivity in heterosexual couples. JAMA 1993; 269: 361–5

    PubMed  CAS  Google Scholar 

  38. Brettler DB, Mannucci PM, Gringeri A, et al. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophiliac males: an international, multi-center study. Blood 1992; 80: 540–3

    PubMed  CAS  Google Scholar 

  39. Akahane Y, Kojima M, Tsubota A, et al. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med 1994; 120: 748–52

    PubMed  CAS  Google Scholar 

  40. Chayama K, Kobayashi M, Tsubota A, et al. Molecular analysis of intraspousal transmission of hepatitis C virus. J Hepatol 1995; 22: 431–9

    PubMed  CAS  Google Scholar 

  41. Nakashima K, Ikematsu H, Hayashi J, et al. Intrafamilial transmission of hepatitis C virus among the population of an endemic area of Japan. JAMA 1995; 274: 1459–61

    PubMed  CAS  Google Scholar 

  42. Zeldis JB, Depner TA, Kuramoto IK, et al. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med 1990; 112: 958–60

    PubMed  CAS  Google Scholar 

  43. Hayashi J, Nakashima K, Kajiyama W, et al. Prevalence of antibody to hepatitis C virus in hemodialysis patients. Am J Epidemiol 1991; 134: 651–7

    PubMed  CAS  Google Scholar 

  44. Hayashi J, Nakashima K, Yoshimura E, et al. Prevalence and role of hepatitis C viraemia in haemodialysis patients in Japan. J Infect 1994; 28: 271–7

    PubMed  CAS  Google Scholar 

  45. Okuda K, Hayashi H, Kobayashi S, et al. Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients. J Hepatol 1995; 23: 28–31

    PubMed  CAS  Google Scholar 

  46. Allander T, Medin C, Jacobson HS, et al. Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virol 1994; 43: 415–9

    PubMed  CAS  Google Scholar 

  47. DeLamballerie X, Olmer M, Bouchouareb D, et al. Nosocomial transmission of hepatitis C virus in haemodialysis patients. J Med Virol 1996; 49: 296–302

    CAS  Google Scholar 

  48. Hayashi J, Kishihara Y, Yamaji K, et al. Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol 1995; 90: 794–9

    PubMed  CAS  Google Scholar 

  49. Nakashima K, Hayashi J, Hirata M, et al. Hepatitis C virus infection on Iki Island, Japan, an area endemic for human T-lymphotropic virus type-I: a preliminary study in patients at clinics or hospitals. J Epidemiol 1994; 4: 17–23

    Google Scholar 

  50. Chiaramonte M, Stroffolini T, Lorenzoni U, et al. Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy. J Hepatol 1996; 24: 129–34

    PubMed  CAS  Google Scholar 

  51. Conry-Cantilena C, Van Raden M, Bibble J, et al. Route of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691–6

    PubMed  CAS  Google Scholar 

  52. Hayashi J, Hirata M, Nakashima K, et al. Hepatitis C virus is a more likely cause of chronic liver disease in the Japanese population than hepatitis B virus. Fukuoka Acta Med 1991; 82: 648–54

    PubMed  CAS  Google Scholar 

  53. Hayashi J, Kishihara Y, Yamaji K, et al. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology 1997; 25: 697–701

    PubMed  CAS  Google Scholar 

  54. Alberti A, Morsica G, Chemello L, et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697–8

    PubMed  CAS  Google Scholar 

  55. Prieto M, Olaso V, Verdu C, et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995; 22: 413–7

    PubMed  CAS  Google Scholar 

  56. Brillanti S, Foli M, Gainnani S, et al. Persistent hepatitis C viraemia without liver disease. Lancet 1993; 341: 464–5

    PubMed  CAS  Google Scholar 

  57. Sakai Y, Izumi N, Tazawa J, et al. Characteristics of anti-HCV antibody-positive patients with hepatocellular carcinoma on chronic hemodialysis: recommendation of periodic ultra-sonography for early detection. Nephron 1996; 74: 386–9

    PubMed  CAS  Google Scholar 

  58. Realdi G, Alberti A, Rugge M, et al. Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut 1982; 23: 270–5

    PubMed  CAS  Google Scholar 

  59. Kiyosawa K, Tanaka E, Sodeyama K, et al. Transmission of antibody to hepatitis C virus from chronic hepatitis to hepatocellular carcinoma. Jpn J Cancer Res 1990; 81: 1089–91

    PubMed  CAS  Google Scholar 

  60. Takano S, Yokosuka O, Imazeki F, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650–5

    PubMed  CAS  Google Scholar 

  61. Dienes HP, Popper H, Arnold W, et al. Histologic observations in human hepatitis non-A, non-B. Hepatology 1982; 2: 562–71

    PubMed  CAS  Google Scholar 

  62. Lechmann M, Ihlenfeldt HG, Braunschwiger I, et al. T- and B-cell response to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 1996; 24: 790–5

    PubMed  CAS  Google Scholar 

  63. Hayashi J, Kishihara Y, Yamaji K, et al. Serum levels of soluble interleukin-2 receptors and effects of interferon-α for patients with chronic hepatitis C virus. Dig Dis Sci 1995; 40: 1837–41

    PubMed  CAS  Google Scholar 

  64. Kishihara Y, Hayashi J, Yoshimura E, et al. IL-lb and TNF-α produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1996; 41: 315–21

    PubMed  CAS  Google Scholar 

  65. Kita H, Moriyama T, Kaneko T, et al. A helper T-cell antigen enhances generation of hepatitis C virus-specific cytotoxic T lymphocytes in vitro. J Med Virol 1995; 45: 386–91

    PubMed  CAS  Google Scholar 

  66. Cacciarelli TV, Martinez OM, Gish RG, et al. Immunoregula-tory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996; 24: 6–9

    PubMed  CAS  Google Scholar 

  67. Napoli J, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996; 24: 759–65

    PubMed  CAS  Google Scholar 

  68. Berger A, Prondzinski MVD, Doerr HW, et al. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. J Med Virol 1996; 48: 339–43

    PubMed  CAS  Google Scholar 

  69. Yoshimura E, Hayashi J, Ueno K, et al. No significant changes in levels of hepatitis C virus (HCV) RNA by competitive polymerase chain reaction in blood samples from patients with chronic HCV infection. Dig Dis Sci 1997; 42: 772–7

    PubMed  CAS  Google Scholar 

  70. Nousbaum JB, Pol S, Nalpas B, et al. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122: 161–8

    PubMed  CAS  Google Scholar 

  71. Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 1996; 125: 634–9

    PubMed  CAS  Google Scholar 

  72. Yamada M, Kakumu S, Yoshioka K, et al. Hepatitis C virus genotypes are not responsible for development of serious liver disease. Dig Dis Sci 1994; 39: 234–9

    PubMed  CAS  Google Scholar 

  73. Yatsuyanagi H, Koike K, Yasuda K, et al. Hepatitis C virus genotypes and development of hepatocellular carcinoma. Cancer 1995; 76: 1352–5

    Google Scholar 

  74. Chen TZ, Wu JC, Yen FS, et al. Injection with nondisposable needles as an important route for transmission of acute community-acquired hepatitis C virus infection in Taiwan. J Med Virol 1995; 46: 247–51

    PubMed  CAS  Google Scholar 

  75. Hagan H, Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health 1995; 85: 1531–7

    PubMed  CAS  Google Scholar 

  76. Krawczynski K, Alter MJ, Tankersley DL, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996; 173: 822–8

    PubMed  CAS  Google Scholar 

  77. Nakano Y, Kiyosawa K, Sodeyama T, et al. Acute hepatitis C transmitted by needlestick accident despite short duration interferon treatment. J Gastroenterol Hepatol 1995; 10: 609–11

    PubMed  CAS  Google Scholar 

  78. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci US A 1994; 91: 1294–8

    CAS  Google Scholar 

  79. Davis GL, Baiart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multi-center randomized, controlled trial. N Engl J Med 1989; 321: 1501–6

    PubMed  CAS  Google Scholar 

  80. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506–10

    PubMed  Google Scholar 

  81. Hagiwara H, Hayashi N, Mita E, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-a. Hepatology 1992; 15: 37–41

    PubMed  CAS  Google Scholar 

  82. Hayashi J, Ohmiya M, Kishihara Y, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994; 89: 2151–6

    PubMed  CAS  Google Scholar 

  83. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051–5

    PubMed  CAS  Google Scholar 

  84. Marcellin P, Boyer N, Giostra E, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393–7

    PubMed  CAS  Google Scholar 

  85. Chemello L, Cavalletto L, Casarin C, et al. Persistent hepatitis C viremia predicts late response after sustained response to interferon-alpha in chronic hepatitis C. Ann Intern Med 1996; 124: 1058–60

    PubMed  CAS  Google Scholar 

  86. Hayashi J, Kishihara Y, Ueno K, et al. Age related response to interferon in women with chronic hepatitis C virus infection. Arch Intern Med. In press

  87. Bresci G, Corso LD, Romanelli AM, et al. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-pos-itive chronic active hepatitis. J Am Geriatr Soc 1993; 41: 857–62

    PubMed  CAS  Google Scholar 

  88. Horüke N, Matsumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995; 10: 246–9

    Google Scholar 

  89. Garson JA, Brillanti S, Whitby M, et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol 1995; 45: 348–53

    PubMed  CAS  Google Scholar 

  90. Shimizu YK, Hijikata M, Iwamoto A, et al. Neutralizing antibodies against hepatitis C virus and emergence of neutralization escape mutant viruses. J Virol 1994; 68: 1494–500

    PubMed  CAS  Google Scholar 

  91. Milella M, Antonelli G, Santantonio T, et al. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 1993; 13: 146–50

    PubMed  CAS  Google Scholar 

  92. Tassopoulos NC, Karvountzis G, Touloumi G, et al. Comparative efficacy of a high or low dose of interferon α2b in chronic hepatitis C: a randomized controlled trial. Am J Gastroenterol 1996; 91: 1734–8

    PubMed  CAS  Google Scholar 

  93. Fattovich G, Guistina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. 1996; 24: 38–47

    CAS  Google Scholar 

  94. Berris B, Feinman SV. Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis. Dig Dis Sci 1991; 36: 1657–60

    PubMed  CAS  Google Scholar 

  95. Silva M, Li X, Cheinquer H, et al. HCV associated idiopathic thrombocytopenic purpura [abstract]. Gastroenterology 1992; 102: A889

    Google Scholar 

  96. Wandl UB, Nagel-Hiemke M, May D, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloprolif-erative disorders. Clin Immunol Immunopathol 1992; 65: 70–4

    PubMed  CAS  Google Scholar 

  97. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897–903

    PubMed  CAS  Google Scholar 

  98. Puoti C, Magrini A, Filippi T, et al. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease. Eur J Gastroenterol Hepatol 1995; 7: 151–4

    PubMed  CAS  Google Scholar 

  99. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995; 23(S2): 13–6

    PubMed  CAS  Google Scholar 

  100. Tsutsumi M, Takada A, Takase S, et al. Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study. J Gastroenterol Hepatol 1996; 11: 1006–11

    PubMed  CAS  Google Scholar 

  101. Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Shosaiko-to (TJ-9). Cancer 1995; 76: 743–9

    PubMed  CAS  Google Scholar 

  102. Hayashi J, Kajiyama W, Noguchi A, et al. Glycyrrhizin withdrawal followed by human lymphoblastoid interferon in the treatment of chronic hepatitis B. Gastroenterol Jpn 1991; 26: 742–6

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Medicine, Kyushu University Hospital, Higashi-ku, Fukuoka, 812-82, Japan

    Jun Hayashi & Seizaburo Kashiwagi

Authors
  1. Jun Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seizaburo Kashiwagi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hayashi, J., Kashiwagi, S. Hepatitis C Virus Infection in the Elderly. Drugs & Aging 11, 296–308 (1997). https://doi.org/10.2165/00002512-199711040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199711040-00005

Keywords

Search

Navigation